This drug is currently being used for preventing clots in knee and hip replacement patients, however was studied for its effects on preventing stroke in atrial fibrillation. The drug was found to be more effective without the need for close monitoring than its predecessor Warfarin.

While not on the market for cardiac patients yet, there is speculations of its release as early as September.

Continue reading →